4 news items
Actinium Pharmaceuticals (ATNM) Reveals Promising Results from SIERRA Trial at EHA Congress
ATNM
BMRN
EXEL
17 Jun 24
. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker-dealer, broker, investment advisor
MAIA Biotechnology (MAIA): Pioneering New Frontiers in NSCLC Treatment with THIO
BMRN
EXEL
GMAB
7 Jun 24
shares of MAIA. InvestorBrandMedia.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
JAZZ
1 Jun 24
endpoint, results demonstrated that a confirmed objective response rate (cORR) by independent central review (ICR) was maintained at 41.3% (95
Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
JAZZ
29 May 24
response rate (cORR) by independent central review (ICR) and results were presented
- Prev
- 1
- Next